Drug Naming Now Costs $28,000 a Word: Inside the USAN, INN, and FDA System That Decides What Every Medicine Is Called
In September 2025, the FDA sent more than 50 warning letters to compounding pharmacies and telehealth sellers of semaglutide and
In September 2025, the FDA sent more than 50 warning letters to compounding pharmacies and telehealth sellers of semaglutide and
In October 2021, the WHO’s INN Expert Group voted to retire the single most recognizable suffix in pharmaceutical nomenclature. Every
The -Mab Suffix Is Dying. Here’s the Naming System Replacing It Read Post »
In November 2014, the FDA changed two letters next to a drug’s name in a government database, and a $1.23
On February 7, 2026, Hims & Hers pulled a $49 compounded copy of Novo Nordisk’s Wegovy pill off the market
Ro vs. Hims & Hers: What the Compounding Crackdown Actually Did Read Post »
The Short Answer A strategy team that wants to license, co-promote, or acquire a drug asset needs to answer four
In the fourteen months after Bristol Myers Squibb agreed to pay up to $14.4 billion for Karuna Therapeutics, its lead
In fiscal year 2021, 167 of the 199 patent settlements pharmaceutical companies filed with the Federal Trade Commission contained a
On June 4, 2026, the Supreme Court ruled 9-0 that Hikma Pharmaceuticals did not induce patent infringement by selling a
Enbrel’s first composition patent expired in 2010. The drug is still exclusive in the United States sixteen years later, and
Sign in or create a free account to read this DrugPatentWatch article